European first in next-generation bacterium: pasteurized Akkermansia muciniphila from A-Mansia Biotech receives the green light from EFSA's scientific committee.
Excellent news for people at risk of
This new fundraising secures the financing of its Phase IIB study for HepaStem® in its flagship indication, Acute on Chronic Liver Failure (ACLF), a severe liver disease affecting more than 50000
LUXEMBOURG, June 29, 2021 – LMO, a company developing precision maneuvering technologies for in-space operations, with offices in Luxembourg and UK, secures funding from VIVES Inter-University Fund,
March 31, 2021 - Louvain-la-Neuve, Belgium: Tessares - a technology company specializing in Hybrid Access software - has just concluded a new round of funding to fast forward an innovative software
LEUVEN, Belgium, March 22nd, 2021 — ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, is proud to announce
Vaccines alone are not enough to fight Covid-19. Experts pinpointed during several occasions on the importance of having antibody-based treatments available in combination with vaccines.
Authorization to start clinical trial in the US granted for rare paediatric bone disease
Mont-Saint-Guibert, Mar 4, 2021 (GlobeNewswire) – Novadip Biosciences (“Novadip”), a clinical stage company
Belgium – 27th January 2021 – Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of the synaptic vesicle protein SV2A for the treatment of cognitive impairment
New funding confirms Aphea.Bio’s frontrunner position in sustainable and innovative agriculture
GENT, NOVEMBER 20 - Aphea.Bio, a Belgium-based agtech startup, announced today that it secured a €14
Tessares, a young company from Louvain-la-Neuve, has won an ultra-selective European subsidy of 1.2 million euros!
In Europe, more than 40% of homes in rural areas do not have a quality internet
ViroVet : Animal health company focused on combatting viral infections in livestock
LEUVEN, Belgium, October 21th, 2020 — ViroVet NV, a leading Belgian biopharmaceutical company active in the